UPDATE: Jefferies Starts Nuvation Bio Inc (NUVB) at Buy
- Wall Street ends week positively; S&P 500, Dow hit record highs
- Bitcoin (BTC) Drops 3% as Turkey Bans Cryptocurrency Payments Citing Lack of Regulatory Supervision
- Morgan Stanley (MS) Archegos-Related Loss Appears to be $911M
- Dollar at 4-week low on retreating Treasury yields
- J&J (JNJ) Privately Asked Rival Covid-19 Vaccine Makers to Inspect Clotting Risks, AstraZeneca (AZN) Said Yes but Pfizer (PFE) and Moderna (MRNA) Declined - Report
Jefferies analyst Michael Yee initiates coverage on Nuvation Bio Inc (NYSE: NUVB) with a Buy rating and a price target of $20.00.
The analyst commented, "We initiate NUVB at BUY based on a deep pipeline of targeted oncology programs in blockbuster markets, strong and proven mgmt, and a strong balance sheet that supports many readouts over the next few years w/ little need for capital. The co has elegant chemistry in multiple high-value cancer areas including CDK2/4/6, BET, WEE1, and very intriguing "PARP drug conjugate" program which is a unique and valuable platform against prostate and breast cancer."
Shares of Nuvation Bio Inc closed at $10.86 yesterday.
You May Also Be Interested In
- Jefferies Starts Tinybuild Inc (TBLD:LN) at Buy
- Empresa Nacional de Telecomunicaciones SA (ENTEL:CI) PT Raised to CLP4,500 at Morgan Stanley
- Localiza Rent a Car S.A. (RENT3:BZ) (LZRFY) PT Lowered to R$67 at Morgan Stanley
Create E-mail Alert Related CategoriesAnalyst Comments, New Coverage
Related EntitiesJefferies & Co
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!